Burmester, G. R., Coates, L. C., Cohen, S. B., Tanaka, Y., Vranic, I., Nagy, E., . . . Kinch, C. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare.
Chicago-referens (17:e uppl.)Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.
MLA-referens (9:e uppl.)Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.